C4 Therapeutics Inc Stock News

Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter, compared to $2.56 in t

These underappreciated opportunities in healthcare are worth a closer look.

C4 Therapeutics <> announced strategic priorities and 2022 milestones to advance its targeted protein degradation portfolio.The initial Phase 1 data for CFT7455, a Novel

– Initial Phase 1 Data for CFT7455, a Novel IKZF1/3 Degrader, Expected in 1H 2022–

WATERTOWN, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that sel

WATERTOWN, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selec

C4 Therapeutics, Inc. (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

C4 Therapeutics, Inc. (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

EMC Capital Management acquired a new position in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 10,619 shares of the companys stock, valued at approximately $472,000. A number of other institutional investors and hedge funds also recently modified their []

C4 Therapeutics, Inc. (NASDAQ:CCCC) Director Malcolm Salter sold 755 shares of the businesss stock in a transaction that occurred on Friday, December 17th. The stock was sold at an average price of $30.25, for a total transaction of $22,838.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible []

Equities research analysts forecast that C4 Therapeutics, Inc. (NASDAQ:CCCC) will post $7.16 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for C4 Therapeutics earnings. The lowest sales estimate is $4.29 million and the highest is $9.00 million. The firm is scheduled to report its next []

WATERTOWN, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that sel

WATERTOWN, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced its inclusion on the NASDAQ Biotechnology Index (Nasdaq: NBI), effective on December 20, 2021.

Bank of America Corp DE decreased its holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC) by 29.7% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 34,305 shares of the companys stock after selling 14,469 shares during the period. Bank of America Corp DE owned approximately 0.07% of []